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Background: The proteins S100B, neuron-specific enolase (NSE), glial fibrillary acidic 
protein (GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), and neurofilament 
light (NF-L) have been serially sampled in serum of patients suffering from traumatic 
brain injury (TBI) in order to assess injury severity and tissue fate. We review the current 
literature of serum level dynamics of these proteins following TBI and used the term 
“effective half-life” (t1/2) in order to describe the “fall” rate in serum.
Materials and methods: Through searches on EMBASE, Medline, and Scopus, we 
looked for articles where these proteins had been serially sampled in serum in human 
TBI. We excluded animal studies, studies with only one presented sample and studies 
without neuroradiological examinations.
Results: Following screening (10,389 papers), n = 122 papers were included. The proteins 
S100B (n = 66) and NSE (n = 27) were the two most frequent biomarkers that were serially 
sampled. For S100B in severe TBI, a majority of studies indicate a t1/2 of about 24 h, even 
if very early sampling in these patients reveals rapid decreases (1–2 h) though possibly of 
non-cerebral origin. In contrast, the t1/2 for NSE is comparably longer, ranging from 48 to 
72 h in severe TBI cases. The protein GFAP (n = 18) appears to have t1/2 of about 24–48 h 
in severe TBI. The protein UCH-L1 (n = 9) presents a t1/2 around 7 h in mild TBI and about 
10 h in severe. Frequent sampling of these proteins revealed different trajectories with 
persisting high serum levels, or secondary peaks, in patients with unfavorable outcome or 
in patients developing secondary detrimental events. Finally, NF-L (n = 2) only increased in 
the few studies available, suggesting a serum availability of >10 days. To date, automated 
assays are available for S100B and NSE making them faster and more practical to use.
Conclusion: Serial sampling of brain-specific proteins in serum reveals different tem-
poral trajectories that should be acknowledged. Proteins with shorter serum availability, 
like S100B, may be superior to proteins such as NF-L in detection of secondary harmful 
events when monitoring patients with TBI.
Keywords: S100B, neuron-specific enolase, glial fibrillary acidic protein, ubiquitin carboxy-terminal hydrolase L1, 
neurofilament light, serum, biomarkers, traumatic brain injury
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iNTRODUCTiON
Globally, traumatic brain injury (TBI) is one of the leading causes 
of death and disability among young adults, and due to sociode-
mographic changes, it is increasing among the elderly (1–3). 
TBI consists of two processes: the initial traumatic impact at the 
scene causing primary damage to the cerebral parenchyma and 
blood vessels, which ca n be followed by the onset of detrimental 
secondary insults (4), characterized by progressive cell death due 
to inflammation, impaired cerebral blood flow and metabolic 
function (5). As cells in the central nervous system are injured/
compromised or succumb, they either secrete, release, or leak 
proteins, some of which are relatively enriched in the CNS (6). 
By measuring these proteins it is possible to assess the extent of 
cellular injury. Unconscious patients suffering from TBI are often 
treated in specialized neurointensive care units (NICU) where 
the goal is to detect, avoid, and treat these secondary insults to 
optimize cerebral recovery. Implementing measurement of these 
proteins of tissue fate (“biomarkers”) into clinical practice may 
help in the detection of secondary injury (7, 8).
The most studied TBI biomarker is S100B (9), a predomi-
nantly intracellular-, calcium-binding protein present primarily 
in mature, perivascular astrocytes (10). Other brain-specific 
proteins that have been extensively studied in TBI include the gly-
colytic enzyme neuron-specific enolase (NSE) (11); the astrocytic 
cytoskeleton component glial fibrillary acidic protein (GFAP) (12); 
ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) involved in 
the neuronal production of ubiquitin (12) as well as neurofilament 
light (NF-L), the smallest component of the axonal cytoskeleton 
(13). Today, S100B is used locally as an early screening tool in the 
Scandinavian Guidelines in mild and moderate TBI (14), where 
low levels in serum have been shown to be able to safely exclude 
the presence of intracranial injury in mild TBI patients and thus 
obviate the needs for head computed tomography in these cases. 
However, it has been suggested that one of the limitations with 
the protein is the relatively short serum elimination half-life 
(suggested to be as short as 25 min in patients with no ongoing 
brain injury) (15). Thus, in patients with mild/moderate TBI 
without pathophysiological processes to cause a sustained release 
in S100B, delayed sampling may be falsely reassuring and this 
is reflected in the guidelines, which suggest a cutoff of 6 h after 
trauma (16). It is becoming increasingly clear that a specific 
level in serum is of little importance if in the absence of kinetic 
considerations.
It is not completely clear how these proteins leave the injured 
brain and enter the blood. Blood–brain barrier (BBB) disruption 
(17) or release independent of BBB integrity (18) as well as pas-
sage through the newly discovered glymphatic system (19) have 
been suggested as possible routes. Presumably, these proteins 
are first released in the brain extracellular space, a component 
difficult to access for repeated sampling (20), before being 
transported to the cerebral spinal fluid (CSF) [where a passive 
diffusion from CSF to blood the first 24 h after injury has been 
suggested (21)] and/or subsequently into serum where it is most 
easily sampled. However, there are several factors that may influ-
ence this transport and thus the availability in serum, including 
clearance, redistribution, protein stability, and ongoing release 
from the damaged brain (22). The protein S100B has been shown 
to have a 100% renal clearance (23), and may thus be affected in 
patients with renal insufficiency (15, 24, 25). Studies regarding 
serum clearance for the other biomarkers are scarce, but as they 
are larger, it is probable that liver metabolism is involved (26).
Thus, the serum concentrations of these biomarkers over time 
are the net sum of complex wash-in (“leak” from the injured 
brain) and washout (clearance and elimination from the blood) 
processes that are variable over time, together creating a profile 
with an expected peak time and a decay rate. This “fall” rate after 
peak gives rise to what is here termed the effective half-life (t1/2). 
This process may vary under different conditions and over time 
in a way that has not yet been properly studied in biomarker 
research and is distinct from the elimination half-life. Because 
of this, it will not be possible to present accurate true serum 
half-lives of these proteins in TBI cohorts. However, composite 
peak times and biological half-lives can to some extent be grossly 
estimated from the literature. In this review, we have chosen 
to focus specifically on these serum trajectories and temporal 
profiles after TBI.
While there have been several systematic review articles 
addressing the utility of different biomarkers in detecting injury 
and predicting outcome (16, 27, 28), there are no studies that 
have systematically integrated the current knowledge concerning 
serial sampling of serum biomarkers in brain injured patients, 
with the goal of suggesting interpretation of levels and estimating 
peak times and biological half-lives. Understanding the temporal 
profiles of biomarkers is crucial, as it will provide pertinent 
information on how to interpret trends. Additionally, current 
and ongoing studies assessing treatment efficacy (29) as well 
as multicenter TBI studies such as CENTER-TBI are providing 
researchers with large cohorts of serial serum samples, where the 
utility of serial sampling in monitoring secondary events could 
be assessed (30).
Aim
By systematically and comprehensively reviewing the available 
literature on serial serum biomarker sampling in human TBI, we 
wish to assess temporal trajectories in order to better understand 
serum t1/2 of these proteins.
MATeRiALS AND MeTHODS
A systematic review was performed, using the methodology 
outlined in the Cochrane Handbook for Systematic Reviewers 
(31). Data were reported following the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) (see Data 
Sheet S1 in Supplementary Material for PRISMA checklist) (32).
Search Question and Population  
of interest
The main question posed for this scoping systematic review was 
as follows: How do serum S100B, NSE, GFAP, UCH-L1, and 
NF-L levels change with time following TBI? Thus, we aimed to 
include all studies reporting at least two serum samples of S100B, 
NSE, GFAP, UCH-L1, or NF-L (respectively) in human TBI. The 
FigURe 1 | Illustrating the selection of articles with serial sampling of S100B.
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primary outcome of interest was serum dynamics, and the result-
ing effective serum half-life (t1/2), over time for these proteins.
inclusion/exclusion Criteria
Inclusion Criteria
All studies including human subjects with TBI, any study size, 
any age category, and reporting at least two serum samples of 
either/or S100B, NSE, GFAP, UCH-L1, and/or NF-L.
Exclusion Criteria
Animal studies, non-TBI studies, studies without neuroradio-
logical examinations, studies analyzing the biomarker in other 
bodily compartments than serum, non-English studies (very 
few available, only one such study n =  1 for S100B was found 
that could otherwise have been potentially included), meeting 
abstracts, and studies failing to adequately demonstrate data from 
multiple sampling.
Search Strategies
MEDLINE, EMBASE, and SCOPUS from December 1, 1945 to 
January 31, 2017 were searched using similar search strategies, 
which were individualized for each database interface. The 
search strategy using MEDLINE and EMBASE can be seen in 
Data Sheet S2 in Supplementary Material, with a similar search 
strategy utilized for the other database. All possible MESH-
terms were used for the different biomarkers (Data Sheet S2 in 
Supplementary Material). Reference lists of any review articles 
on this subject were reviewed for any missed relevant studies.
Study Selection
Utilizing two reviewers, a two-step review of all articles returned 
by our search strategies was performed. First, the reviewers inde-
pendently (Frederick Adam Zeiler and Eric Peter Thelin) screened 
titles and abstracts of the returned articles to decide if they met 
the inclusion criteria. Any meeting abstracts returned by the 
search strategy were not included in the final review. However, we 
hand searched the abovementioned databases for any published 
manuscripts corresponding to these meeting abstracts, prior to 
discarding them. Second, full texts of the chosen articles were 
then assessed, to confirm if they met the inclusion criteria and 
that the primary outcome of interest was reported in the study 
(Frederick Adam Zeiler and Eric Peter Thelin). Any discrepancies 
between the two reviewers were resolved by a third reviewer if 
needed (Adel Helmy or David K. Menon).
Data extraction
Using a tailored form, data were extracted from the selected 
articles and stored in an electronic database. Data fields included 
the following: number of patients, patient demographics [age and 
injury severity, usually based on Glasgow Coma Scale (GCS) (33)], 
type of assay used (technique and manufacturer, if available), 
sampling frequency, trend over time for the specific biomarker 
(looking at serum data either in tables or figures presented in the 
articles), estimated temporal profile/serum availability, and any 
specific notes concerning the serial sampling of the biomarker. As 
delta values were not provided, to calculate the t1/2 the concentra-
tion decrease was divided by time. So, if the first concentration 
following the peak was 0.50 µg/L and a second sample acquired 
after 12 h was 0.25 µg/L, it would have resulted in a t1/2 of 12 h. 
If the serum concentration initially increased, the decrease fol-
lowing the peak concentration was used (and was commented 
on in “notes”). If the concentration only increased over time, it 
was commented on, and no t1/2 was calculated. In the case of long 
sampling frequency, a non-accurate range for the effective serum 
half-life was noted.
Quality/Bias Assessment
As only three S100B studies and one UCH-L1 study (29–32) 
investigated serum dynamics over time, a formal bias assessment 
of all the included studies is not possible. However, as the goal of 
this review was to produce a systematically conducted review of 
the available literature on serial sampling of serum biomarkers 
in TBI, this is not critical. Our main aim was instead to produce 
a comprehensive overview of the current literature on the topic.
Statistical Analysis
Due to the heterogeneity of the data, both between severity 
grades of included TBI patients and varying sampling times and 
assays used, we could not perform a formal meta-analysis of the 
collected data. However, we did make histograms for the different 
biomarker studies with a sampling frequency of 24 h or less that 
indicated an estimate of t1/2.
ReSULTS
S100B
A search for S100B identified a total of 3,113 manuscripts. 
Following removal of duplicates and after assessing full 
manuscripts, 66 articles were deemed eligible for final inclusion 
(Figure 1) and are listed in Table 1.
TABLe 1 | Analysis of S100B studies.
Reference Number of 
patients
Patient 
characteristics
S100B assay Sampling 
frequency
Trend over time Suggested 
effective half-life
Notes
Akhtar  
et al. (62)
17 (7 with 
TBI)
Pediatric 
(5–18 years), mild 
TBI
Liaison, 
Sangtec 
6 h (only 
two 
samples)
Decreases first 12 h after 
trauma
None stated, >6 h No specific kinetic monitoring. 
Higher levels in patients with 
lesions on MRI
Baker  
et al. (34)
64 Adult, severe TBI 
patients (GCS < 9)
ELISA, 
Nanogen 
Corp.
Initially, 
12 h
Decreases first 48 h after 
trauma, does not reach control 
levels
None stated, <12 h No specific kinetic monitoring. 
Higher levels in patients not 
treated with hypertonic saline
Berger  
et al. (67)
100 Pediatric, inflicted 
and non-inflicted 
TBI cases. GCS 
3–15
ELISA, 
Nanogen 
Corp.
12 h Inflicted TBI longer time-to-
peak S100B than non-inflicted 
TBI
None stated, not 
enough data to 
suggest one
Worse GCS have longer 
time-to-peak
Blyth  
et al. (68)
10 Adult (39–63 years) 
mild-to-severe 
(3–14) TBI
ELISA, 
Nanogen 
Corp.
Initially 12 h S100B levels reach healthy 
control after 48 h
None stated, 
24–48 h
Levels all time below reference 
levels
Buonora  
et al. (69)
154 (106 
with TBI)
Adult mild-to-
severe TBI (GCS 
3–15)
TBI 6-Plex, 
MSD
>48 h Decreasing quickly over time None stated, <6 h No specific outcome 
concerning biomarker kinetics
Chabok  
et al. (35)
28 Adult, severe 
(GCS < 9) diffuse 
axonal injury TBI
ELISA, CanAg 
Diagnostics
About 24 h Decreases quickly over time None stated, 
difficult to say, 
<24 h
Later S100B levels better 
outcome predictors
Chatfield  
et al. (70)
20 Adult (16–
60 years), 
moderate-to-
severe (GCS 3–11) 
TBI
LIA-mat, 
Sangtec
24 h Decreases over time, reaches 
control after 5 days
None stated, about 
24 h
No specific outcome 
concerning biomarker kinetics
DeFazio  
et al. (36)
44 Adult (16–64 years) 
severe (GCS 3–8) 
TBI
Unknown 24 h Decreases the first 72 h None stated, <24 h Higher levels in patients with 
unfavorable outcome
Di Battista  
et al. (71)
85 Adult moderate-to-
severe TBI
Multiplex 
immunoassay 
system, MSD
Initially, 
every 6 h
Quickly declining the first 24 h None stated, <6 h Higher levels in patients with 
unfavorable outcome
Dimopoulou  
et al. (37)
47 Adult (17–
75 years), severe 
(GCS < 9) TBI
LIA-mat, 
Sangtec
24 h Decreases in non-brain dead 
patients until day 5. Increase in 
brain dead patients
None stated, 
3 days in non-brain 
dead patients
Higher levels and more volatility 
in brain dead patients
Elting et al.  
(72)
10 Adult, moderate-
to-severe (GCS 
3–13) TBI
LIA-mat, 
Sangtec
24 h Decreases the first days, 
baseline after about 9 days
None stated, about 
3 days
No specific outcome 
concerning biomarker kinetics
Enochsson  
et al. (63)
19 Adult, mild TBI 
patients
LIA-mat, 
Sangtec
4 h (one 
sample 
only)
Returns to normal within 4–6 h 4–6 h suggested, 
looks probable in 
most patients
No different in kinetics with 
ethanol in the blood
Ercole  
et al. (73)
154 Adult, mild-to-
severe (GCS 3–15), 
NICU TBI
CLIA, Liaison, 
DiaSorin 
and ECLIA, 
Elecsys, 
Roche
12 h S100B peaks at 27.2 h None stated, 
varying over time
Kinetics specifically mapped 
in patients without secondary 
peaks of S100B
Ghori  
et al. (38)
28 Adult (18–
65 years), severe 
(GCS 3–7) TBI
LIA-mat, 
Sangtec
24 h Good outcome patients 
stabilize after 3 days, poor 
outcome patients increased 
even after 5 days
None stated, 24 h 
in patients with 
good outcome, 
72 h in patients with 
poor outcome
Higher levels in patients with 
unfavorable outcome
Goyal  
et al. (21)
80 Adult, severe 
(GCS < 9) TBI
ELISA, 
Nanogen 
Corp.
24 h Slowly decreasing levels 
(peak at 24 h), more quickly 
decrease in patients with good 
outcome the first 5 days
None stated, about 
24 h in patients with 
favorable outcome 
and 72 h in patients 
with unfavorable 
outcome
Possible to divide patients in 
trajectory groups where higher 
levels over time are correlated 
with an unfavorable outcome
(Continued )
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Reference Number of 
patients
Patient 
characteristics
S100B assay Sampling 
frequency
Trend over time Suggested 
effective half-life
Notes
Herrmann  
et al. (74)
69 Adult (16–67 years) 
mild-to-severe 
TBI patients (GCS 
3–15)
LIA-mat 
system, 
Sangtec
About 24 h Quickly declining first 12 h, 
then a plateau until 73 h
None stated, 
presumably <12 h
Earlier samples better for 
outcome prediction
Herrmann  
et al. (75)
66 Adult (16–65 years) 
mild-to-severe 
TBI patients (GCS 
3–15)
LIA-mat 
system, 
Sangtec
24 h Slowly declining, in some 
pathologies secondary peaks 
occurred
None stated, 
presumably about 
24–48 h
Higher in different types of 
pathologies over time (diffuse 
axonal injury and edema)
Herrmann  
et al. (76)
69 Adult (16–65 years) 
mild-to-severe 
TBI patients (GCS 
3–15)
LIA-mat 
system, 
Sangtec
24 h Relatively slow decline over 
96 h
None stated, 
presumably 
49–72 h
Higher area under curve levels 
in unfavorable outcome. 
S100B increased 2 weeks and 
6 months after injury
Honda  
et al. (77)
34 (18 TBI 
patients)
Adult ED TBI 
patients (GCS 
5–14)
ELISA, 
Yanaihara 
Institute
24 h Constantly increased the first 
3 days
None stated, 
presumably >72 h
No specific analysis on 
biomarker kinetics
Ingebrigtsen  
et al. (64)
50 (10 
patients 
highlighted)
All ages 
(6–88 years), mild 
(GCS 14–15) TBI 
patients
LIA-mat 
system, 
Sangtec
6–12 h 
(only two 
samples)
Rapidly decreasing the first 
12 h
None stated, <12 h Early sampled S100B samples 
decrease rapidly
Ingebrigtsen 
and Romner 
(65)
2 All ages 
(12–73 years), mild 
(GCS 14–15) TBI 
patients
LIA-mat 
system, 
Sangtec
1 h Decreasing the first 8 h in 
patients with injuries on MRI
None stated, about 
6 h
Patients with injuries on MRI 
have elevated S100B levels
Jackson  
et al. (39)
30 Severe TBI patients ILA, 
Byk-Sangtec
3–4 h 
(only two 
samples)
Decreasing the first 240 h. 198 min (100 
to >500 min 
presented)
The patients with the highest 
levels had the most rapid 
decreases
Joseph  
et al. (40)
40 Adult (>17 years), 
severe (GCS < 9) 
TBI
ELISA, 
BioVendor
Initially 6, 
then 18 h
Patients with remote ischemic 
conditioning decrease over 
time
None stated, >24 h No specific analysis on 
biomarker kinetics
Kellermann  
et al. (78)
57 Adult, moderate-
to-severe TBI
ECLIA, 
Elecsys, 
Roche
24 h Decreasing the first 4–5 days None stated, about 
96 h
No specific analysis on 
biomarker kinetics. Significant 
decrease over time
Kleindienst  
et al. (18)
71 Adult (>17 years), 
mainly severe TBI
ECLIA, 
Cobas, Roche
24 h Steadily decreasing, under 
reference levels after 20 days
None stated, about 
48–72 h
Does not seem to be a kinetic 
association between CSF and 
serum
Kleindienst  
et al. (79)
19 Adult, severe TBI ECLIA, 
Elecsys, 
Roche
24 h Initial peak to day 2, then 
decline the first 10 days
None stated, about 
96 h
No specific analysis on 
biomarker kinetics
Korfias  
et al. (41)
112 Adult (16–
86 years), severe 
(GCS < 9) TBI
LIA-mat 
system, 
Sangtec
24 h Decreasing steadily for 
survivors, plateau in 96 h. 
Remaining increased in 
non-survivors
None stated, about 
48 h in survivors 
and a lot longer in 
non-survivors
Neurological deterioration 
during the clinical course is 
related to increases in S100B
Li  
et al. (42)
159 Adult (15–71 years) 
severe (GCS < 9) 
TBI
ELISA, 
unknown 
origin
3 days Decreases over time, very slow 
decrease in control group
None stated, 
14 days in the 
treated group, 
>3 months in the 
control group
Lower S100B levels over time in 
the erythropoietin group
McKeating  
et al. (80)
21 Adult (17–69 years) 
moderate-to-
severe (GCS 3–13) 
TBI
LIA-mat 
system, 
Sangtec
24 h Decrease over time, up to 
48 h, some outliers with 
increasing levels
None stated, 
presumably >24–
48 h in unaffected 
patients
More volatility in patients with 
unfavorable outcome
Mofid  
et al. (81)
32 Adult, mild-to-
moderate TBI
ELISA, 
BioVendor
24 h and 
5 days
Decreasing, and plateauing 
during 24 h for the 
progesterone group, while 
constantly increased for 
controls
None stated, <24 h 
in treated patients 
and >6 days in 
controls
Lower S100B levels over time in 
the progesterone group
(Continued )
TABLe 1 | Continued
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Reference Number of 
patients
Patient 
characteristics
S100B assay Sampling 
frequency
Trend over time Suggested 
effective half-life
Notes
Murillo-
Cabezas  
et al. (43)
87 Adult (15–
76 years), severe 
(GCS < 9) TBI
ECLIA, 
Elecsys, 
Roche
24 h Decreasing the first 3 days None stated, 
24–48 h
Longer serum half-life in 
patients with unfavorable 
outcome
Nirula  
et al. (82)
16 Adult mild-to-
severe TBI 
ILA system, 
Sangtec
24 h Decrease first 3 days, then 
stabilizing
None stated, 
presumably < 24 h
Higher levels in patients with 
placebo treatment
Nylén  
et al. (44)
59 All age 
(8–81 years), 
severe (GCS < 9) 
TBI
ELISA, 
Fujirebio
24 h Decrease the first 4 days, then 
plateauing
None stated, 
24–48 h
S100BB and S100A1B have 
slower declines in serum than 
S100B
Olivecrona  
et al. (45)
48 Adult (15–
63 years), severe 
(GCS 3–8) TBI
CLIA, Liaison, 
Sangtec
12 h Elevated first 4 days, then 
steep decrease
None stated, 
presumably about 
120 h
Worse correlation between NSE 
and S100B as time progresses
Olivecrona 
and 
Koskinen 
(46)
48 Adult, severe 
(GCS < 9) TBI 
patients
CLIA, Liaison, 
Sangtec
12 h Decrease the first 2 days, then 
stabilizing in ApoE4 groups. 
Longer time elevated in non-
Apo-E4 patients
None stated, about 
48 h in Apo-E4 
groups, longer 
in non-Apo-E4 
patients
APO-E4 patients have lower 
S100B levels over time
Olivecrona  
et al. (47)
48 Adult, severe 
(GCS < 9) TBI 
patients
CLIA, Liaison, 
Sangtec
12 h Decrease the first three days, 
then stabilizing
None stated, about 
80 h
Later S100B levels better for 
outcome prediction
Pelinka et al. 
(83)
79 Adult, mild-to-
moderate TBI
LIA-mat 
system, 
Sangtec
24 h Quick decrease for early <12 h 
samples to 12–36 h. Decrease 
the first 108 h
None stated, about 
<12 h
Later S100B levels better for 
outcome prediction
Pelinka  
et al. (48)
46 Adult, severe 
(GCS < 9) TBI
LIA-mat 
system, 
Sangtec
24 h Very high early levels that 
stabilize after 96 h, especially 
in multitrauma patients
None stated, 
12–24 h
Brain injuries more prolonged 
release than extracranial trauma
Pelinka  
et al. (84)
92 Adult, mild-to-
severe TBI patients
CLIA, Liaison, 
Sangtec
24 h Very high early levels 
(especially in non-survivors) 
that stabilize after about 60 h
None stated, 
12–24 h
Later S100B levels better for 
outcome prediction
Petzold  
et al. (86)
21 Adult, mild-to-
severe TBI
ELISA, 
custom made
24 h High levels in non-survivors 
that decrease over time. 
Little change in survivors that 
have similar levels as healthy 
controls after 6 days
None stated, 
about 72 h for 
non-survivors
Difficult to compare the levels, 
are a lot higher than other 
studies
Petzold  
et al. (85)
14 Adult (23–
56 years), severe 
TBI
ELISA, 
custom made
24 h Slight increase the first day, 
then a steady decline the first 
6 days
None stated, about 
6 days
Timing important for S100B 
interpretation
Piazza  
et al. (87)
12 Pediatric 
(1–15 years), mild-
to-severe (GCS 
3–15) TBI
CLIA, Liaison, 
Sangtec
48 h 
(only two 
samples)
Very heterogeneous 
trajectories for different 
patients
None stated, not 
possible to say
No specific analysis on 
biomarker kinetics
Pleines  
et al. (49)
13 Adult (16–
67 years), severe 
TBI (GCS < 9)
ELISA, 
Sangtec
24 h Drops relatively quick, “normal” 
levels after 5 days
None stated, 
difficult due to log 
data but probably 
48–72 h
No specific analysis on 
biomarker kinetics
Raabe  
et al. (50)
15 Adult (19–
58 years), severe 
(GCS < 9)
LIA-mat, 
Sangtec
24 h Some patients increase, other 
steady over time, while many 
decrease the first 5 days
None stated, 
difficult to say due 
to few patients, 
probably about 
48 h in a majority of 
patients
Patients with secondary 
increases have a more 
unfavorable outcome
Raabe and 
Seifert (51)
3 Adult (17–
55 years), severe 
(GCS < 9) TBI
Unknown 24 h Secondary increases in three 
patients
None stated, 
impossible to say
Secondary increases lead to 
fatal outcome
TABLe 1 | Continued
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Reference Number of 
patients
Patient 
characteristics
S100B assay Sampling 
frequency
Trend over time Suggested 
effective half-life
Notes
Raabe  
et al. (88)
84 Adult (16–
85 years), severe 
(GCS < 9) TBI
LIA-mat, 
Sangtec
24 h Very diverse temporal 
trajectories in non-surviving 
patients, steady decline in 
surviving patients
None stated, 
difficult to say for 
non-survivors, 
probably 24–48 h in 
survivors
Later samples better for 
outcome prediction
Raabe and 
Seifert (89)
25 Adult (18–
78 years), severe 
(GCS < 9) TBI
LIA-mat, 
Sangtec
24 h Very dynamic trajectory in 
patients with unfavorable 
outcome, steady decline 
in patients with favorable 
outcome
None stated, about 
72 h in patients with 
favorable outcome
No specific analysis on 
biomarker kinetics
Raabe  
et al. (7)
31 Adult, severe 
(GCS < 9) TBI 
patients
CLIA, Liaison, 
Sangtec
24 h Increase in TBI patient with 
cerebral infarction
None stated, 
difficult to say as 
only one TBI patient 
is illustrated
Secondary peaks correlated 
with a secondary deterioration
Raheja  
et al. (52)
86 Adult (18–
65 years), severe 
TBI (GCS 4–8)
ELISA, 
BioVendor
7 days Decrease the first 7 days None stated, 
<7 days
No specific analysis on 
biomarker kinetics
Rodriguez-
Rodriguez  
et al. (53)
56 Adult, severe TBI 
(GCS < 9)
ECLIA, 
Elecsys, 
Roche
24 h Steady decline, the first 96 h None stated, about 
24 h
Admission samples worse 
than 24 h S100B samples for 
outcome
Rodriguez-
Rodriguez  
et al. (54)
99 Adult, severe TBI 
(GCS 3–8)
ECLIA, 
Elecsys, 
Roche
24 h Decreasing the first 96 h, 
greater decrease in patient 
with better outcome
None stated, 
presumably 24 h for 
both survivors and 
non-survivors
72 h S100B is best for outcome 
prediction
Rothoerl  
et al. (55)
15 Adult (17–
73 years), severe 
(GCS < 9) TBI
RIA, 
Byk-Sangtec
Initially 6, 
then 24 h
Patients with unfavorable 
outcome peak at 6 h 
after admission and then 
decreasing, favorable outcome 
patients decrease constantly
None stated, <6 h 
in patients with 
favorable outcome 
and 24 h with 
unfavorable
No specific analysis on 
biomarker kinetics
Shahim  
et al. (56)
72 Adult, severe 
(GCS < 9) TBI 
ECLIA, 
Cobas, Roche 
24 h Decreases steadily over time 
(12 days). All normal after 
1 year
Not mentioned, 
24–48 h
No specific analysis on 
biomarker kinetics
Shakeri  
et al. (57)
72 All ages 
(5–80 years), 
severe (GCS < 9) 
TBI
ELISA (?), 
unknown 
origin
Initially 48 h Higher levels in brain dead 
patients after 48 h than in 
favorable outcome
None stated, 
difficult to say 
due to different 
sampling.
Highest in patients diagnosed 
as brain dead
Thelin  
et al. (11)
417 Adult (>14 years 
old), mild-to-severe 
(GCS 3–15) NICU 
TBI patients
CLIA, Liaison, 
DiaSorin 
and Elecsys, 
Roche
12 h Decreasing over the first 60 h, 
faster in patients with favorable 
outcome. Peaks at about 30 h
None stated, about 
<6 h initially but 
longer in later (24 h) 
samples
S100B influenced by 
multitrauma first 10 h. 30-h 
samples best for outcome 
prediction. More volatility and 
higher levels in patients with 
poor outcome
Ucar  
et al. (58)
48 Severe (GCS < 9) 
TBI
LIA-mat, 
Sangtec
48 h Higher levels on day 3 for the 
unfavorable group, otherwise 
unchanged over time
None stated, 
difficult to suggest 
one
Patients with unfavorable 
outcome secondary peaks of 
S100B
Undén  
et al. (59)
1 Severe (GCS3) TBI, 
22 years old
CLIA, Liaison, 
Sangtec
Hourly Very volatile S100B dynamics 
over time in patient with TBI 
that succumbs due to cerebral 
herniation
None stated, 
difficult to suggest 
one
Intracranial perfusion necessary 
for S100B release
Undén  
et al. (90)
29 TBI Adult, mild-to-
moderate, NICU 
TBI
CLIA, Liaison, 
Sangtec
24 h Elevation > 0.5 μg/L harmful 
deterioration
None stated, 
difficult to assess
Strong association between 
S100B levels and secondary 
complications
Vajtr  
et al. (94)
18 Unknown TBI ECLIA, 
Elecsys, 
Roche 
>3 days Decreasing over the first 
7–10 days, more so in the less 
injured group
None stated, 
probably <3 days.
Decreasing a lot quicker in 
patients who did not need 
neurosurgery
Vajtr  
et al. (95)
38 Different types of 
presumably adult, 
severe TBI
ECLIA, 
Cobas, Roche
>3 days Decreasing over 1–3 vs 
4–10 days in all intracranial 
pathologies
None stated, 
<72 h.
Non-expansive contusions 
highest S100B over time
TABLe 1 | Continued
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Reference Number of 
patients
Patient 
characteristics
S100B assay Sampling 
frequency
Trend over time Suggested 
effective half-life
Notes
Walder  
et al. (91)
49 Severe (AIS > 3, 
but GCS 3–10), 
adult TBI
ELISA, 
Abnova Corp.
Initially 6, 
then 24 h
Decreases quickly the first 
12 h, then more stable
None stated, 
presumably around 
6 h
No difference between 
multitrauma and non-
multitrauma patients. Higher 
early S100B levels in patients 
with GCS 3–8
Watt  
et al. (60)
23 Adult (18–
34 years), severe 
(GCS < 9)
LIA-mat, 
Sangtec
24 h Decreases steadily with 
constant half-life the first 
6 days, then leveling
None stated, 
between 24–48 h
Early samples drawn, quick 
decline. High early levels 
associated with an unfavorable 
outcome 
Welch  
et al. (92) 
167 Adult moderate-
to-mild TBI (GCS 
9–15)
ECLIA, 
Cobas, Roche
Every 6 h 
(up to 24 h)
Generally decreasing trends, 
some increase the first 12 h
None stated, some 
shorter but seems 
to <12 h for a 
majority of patients
After about 8 h, all patients with 
extracranial injury levels have 
low levels of S100B
Woertgen  
et al. (66)
30 Adult (17–
73 years), severe 
(GCS 3–8) TBI 
RIA, 
Byk-Sangtec
Initially 6 h Decreasing the first hours, 
then increasing at 24 h with 
a secondary peak, only to 
decline later on the first 120 h
None stated, <6 h 
in early samples but 
with a secondary 
increase
Early levels reveal quick early 
decrease and higher levels in 
patients with more unfavorable 
outcome
Yan  
et al. (61)
42 Adult (16–
63 years), severe 
(GCS < 9) TBI
ELISA, 
Diasorin
24 h Steadily decreasing the first 
5 days, almost reaching same 
levels as seen in healthy 
controls
None stated, 
24–48 h
No specific analysis on 
biomarker kinetics
Zurek and 
Fedora (93)
63 Pediatric 
(0–18 years), 
presumably 
different severity  
of injury
ECLIA, 
Elecsys, 
Roche
24 h Steadily declining the first 
5 days, some outliers with 
higher levels
None stated, <24 h 
for a majority of 
patients. Some 
have secondary 
peaks
Early levels reveal quick early 
decrease and higher levels in 
patients with more unfavorable 
outcome
Number of patients highlighted the total number of patients included in the study, sometimes highlighting in parenthesis how many were actually included with TBI or serial 
sampling. Patient characteristics described the age groups and injury severity level according to the GCS. The assay described the technique used for the assay and if available 
the manufacturer. Sampling frequency illustrates with what frequency samples were acquired. Trewnd over time highlights the specific temporal trajectory and dynamics for S100B. 
Suggested effective serum half-life is noted, as derived from graphs or tables. “Notes” indicate any specific considerations or notable findings of serial sampling in the specific article.
TBI, traumatic brain injury; ECLIA, electrochemiluminescent immunoassay; ELISA, enzyme-linked immunosorbent assay; GCS, Glasgow Coma Scale; ED, emergency department; 
ILA, immunoluminometric assay; RIA, radioimmunoassay; CLIA, chemiluminescent immunoassays; ECLIA, electrochemiluminescent immunoassays; NICU, neurointensive care unit; 
NSE, neuron-specific enolase; CSF, cerebral spinal fluid.
TABLe 1 | Continued
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Patient Characteristics
Generally, the patient characteristics in the S100B studies 
were severely injured TBI patients (GCS  <  9 at admission, 
unconscious) (21, 34–61) and mild (GCS 14–15) (62–66) or in 
combination (including moderate GCS 9–13) (7, 11, 18, 67–92) 
(Table 1). All different age groups were analyzed, including only 
or partial pediatric populations (44, 57, 62, 64, 65, 67, 93), even if 
a vast majority included solely adult patients (7, 11, 18, 21, 34–38, 
40–43, 45–51, 53–56, 59–61, 63, 66, 68, 71–92).
Assays Used to Analyze Serum S100B
The studies used a wide variety of different assays to analyze 
S100B. Commercial or custom made enzyme-linked immuno-
sorbent assays (ELISAs) were used in some studies (21, 34, 35, 
40, 42, 44, 49, 52, 57, 61, 67, 68, 77, 81, 85, 86, 91), as well as 
other techniques (or not mentioned in the text) (36, 51, 55, 
66, 69, 71), even if a majority used clinically available assays 
such as the (C)LIA-mat system from Sangtec/DiaSorin (7, 11, 18, 
37–39, 41, 43, 45–48, 50, 53, 54, 56, 58–60, 62–65, 70, 72–76, 
78–80, 82–84, 87–90, 92–95). In general, ELISA samples showed 
less volatility over time (42, 49, 68, 81, 91). Specifically, they 
tended to have elevated levels over a prolonged period of time 
as compared to the automated, clinical assays (42, 49, 52, 77, 
81, 85, 86, 91).
Sampling Frequency of S100B
While some studies had more than 24  h between sampling 
times (42, 52, 57, 58, 81, 87, 94, 95), generally the studies had a 
sampling frequency of every 24 h (7, 18, 21, 35–38, 41, 43, 44, 
48–51, 53, 54, 56, 60, 61, 70, 72, 74–86, 88–90, 93), or sometimes 
twice daily (11, 34, 45–47, 67, 68, 73), or every 4–6 h (39, 40, 55, 
62–64, 66, 69, 71, 91, 92). In contrast to the other biomarkers, 
there were some studies that assessed S100B hourly in order to 
track the serum dynamics (59, 65).
Trend of S100B over Time after Trauma
Following trauma, almost all articles proclaim a steadily decline 
in levels of S100B (18, 21, 35, 36, 40, 43–48, 52–54, 56, 60, 61, 
64, 69–72, 78, 80–84, 86, 88, 91, 93–95), while some suggested 
a slight increase before declining (55, 73, 79, 85, 92). Patients 
suffering from multitrauma and TBI were seen to have higher 
levels compared to patients with only TBI (11, 48, 92). Generally, 
the decreasing trajectory of S100B was strongly correlated with 
the severity of trauma and/or the outcome for the patient (11, 21, 
FigURe 2 | Histograms of frequency of effective serum half-life in different studies. Histograms illustrating the aggregated effective serum half-lives as derived from 
the different studies including S100B (A), neuron-specific enolase (NSE) (B), glial fibrillary acidic protein (GFAP) (C), and ubiquitin carboxy-terminal hydrolase L1 
(UCH-L1) (D). Studies with a sampling frequency of 24 h or shorter and a valid estimate of the effective serum half-life were included. The bin size is set to 10 h in 
order to easily visualize trends; a relatively short effective serum half-life for S100B and UCH-L1, while it was longer for NSE and GFAP. An effective serum half-life 
for neurofilament light could not be included as it was impossible to estimate from the available literature.
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36–38, 41–43, 50, 54, 55, 58, 60, 62, 65, 66, 71, 75, 84, 86, 93–95). 
Some papers indicate a very quick decline of serum S100B (39, 
49, 83), while some suggest that it is a slower decline over time 
in relation to when the sample is acquired (11, 60, 64, 69, 71, 
73, 74, 85, 93). Several studies indicate volatile S100B trajectories 
in more unstable patients with detrimental outcomes due to 
injury development (37, 38, 41, 50, 57, 59, 66, 67, 80, 84, 87–89). 
Secondary increases (“peaks”) of S100B were found in several 
studies and correlated with secondary adverse events (7, 41, 51, 
58, 75, 90). Some clinical trials noted a faster decrease of S100B 
in serum over time in the trial group as compared to placebo 
(34, 42, 81, 82).
Suggested Serum t1/2 of S100B
Available data suggest that there is a rapid influx and fast t1/2 of 
about 2–6 h in mild TBI patients, which is similar in more severe 
TBI patients if acquired early (11, 34, 39, 55, 63–66, 69, 71, 74, 
83, 91, 92) (Figure 2A). Additionally, a slower influx with a later 
peak and t1/2 of about 24 h the first days in severe TBI patients 
are described (11, 21, 35, 36, 38, 40, 43, 44, 48, 53, 54, 56, 60, 61, 
70, 73, 75, 81, 82, 84, 88, 93). Some studies reported t1/2 of days 
(24–120 h) (18, 21, 37, 41, 45–47, 49, 72, 76–80, 85, 86, 89) or even 
weeks (14 days) (42).
Neuron-Specific enolase
A search for NSE identified a total of 4,511 manuscripts. 
Following the removal of duplicates and after assessing full 
manuscripts, 27 articles were deemed eligible for final inclu-
sion (Figure S1 in Supplementary Material) and are listed in 
Table 2.
Patient Characteristics
Generally, the patient characteristics in the NSE studies were 
very similar to the S100B studies with a variety of primarily 
adult, mild/moderate-to-severely (11, 71, 74–77, 80, 82, 96–98), 
or only severely injured patients (34, 42, 45–47, 49, 52, 54, 61, 66, 
99–101) (Table 2). However, some looked at more minor injuries 
and included pe diatric patients (67, 93, 102).
TABLe 2 | Analysis of NSE studies.
Reference Number 
of 
patients
Patient 
characteristics
NSe assay Sampling 
frequency
Trend over time Suggested reactive 
half-life
Notes
Baker  
et al. (34)
70 Adult, severe TBI 
patients (GCS < 9)
ELISA, 
Nanogen 
Corp.
Initially, 
12 h
Decreases quickly after 
trauma
None stated, 12–15 h 
the first hours
No specific kinetic monitoring. 
Higher levels in patients not 
treated with hypertonic saline
Beers  
et al. (102)
30 Pediatric TBI (GCS 
3–15)
ELISA, 
Nanogen 
Corp.
12 h Increases the first 4 days 
in inflicted trauma
None stated, not 
enough data to 
suggest one
Worse outcome if longer time to 
peak levels
Berger  
et al. (67)
100 Pediatric, inflicted, 
and non-inflicted TBI 
cases. GCS 3–15
ELISA, 
Nanogen 
Corp.
12 h Inflicted TBI longer 
time-to-peak NSE than 
non-inflicted TBI
None stated, not 
enough data to 
suggest one
Patients with lower GCS have 
longer time-to-peak
Buonora  
et al. (69)
154 (106 
with TBI)
Adult mild-to-severe 
TBI (GCS 3–15)
TBI 6-Plex, 
MSD
>48 h Decreasing steadily over 
time
None stated, about 
24 h
No specific outcome concerning 
biomarker kinetics
Dauberschmidt 
et al. (99)
9 Severe TBI patients 
(GCS 4)
RIA 24 h Steadily increasing in 
some, unchanged in 
some, over 10 days
None stated, not 
enough data to 
suggest one
No specific outcome concerning 
biomarker kinetics
Di Battista  
et al. (71)
85 Adult moderate-to-
severe TBI
Multiplex 
immunoassay 
system, MSD
Initially, 
every 6 h
Slowly declining the first 
24 h
None stated, 
probably >24 h 
(closer to 48 h)
Primary: First 24 h kinetics 
studied. No difference in NSE 
levels between outcome
Guzel  
et al. (96)
169 Mild-to-severe TBI 
patients
ECLIA, Cobas, 
Roche
24 h Declining over time None stated, 
presumably close to 
48 h for the entire 
cohort
Slower decline in patients with 
more severe injuries
Herrmann  
et al. (74)
69 Adult (16–67 years) 
mild-to-severe TBI 
patients (GCS 3–15)
LIA-mat 
system, 
Sangtec
About 24 h Declining over time, 
stabilizing after 73 h
None stated, 
presumably 48 h
Later samples not better for 
outcome prediction
Herrmann  
et al. (75)
66 Adult (16–65 years) 
mild-to-severe TBI 
patients (GCS 3–15)
LIA-mat 
system, 
Sangtec
24 h Slowly declining, in some 
pathologies secondary 
peaks occurred
None stated, 
presumably 73–96 h
Higher in different types of 
pathologies over time (diffuse 
axonal injury and edema)
Herrmann  
et al. (76)
69 Adult (16–65 years) 
mild-to-severe TBI 
patients (GCS 3–15)
LIA-mat 
system, 
Sangtec
24 h Slowly declining over 
96 h
None stated, 
presumably 49–72 h
No association between 
prolonged increases (6 months) 
of NSE and outcome
Honda  
et al. (77)
34 (18 
TBI 
patients)
Adult ED TBI patients 
(GCS 5–14)
ELISA, Alpha 
Diagnostics
24 h Constantly increased the 
first 3 days
None stated, 
presumably >72 h
No specific analysis on 
biomarker kinetics
Li  
et al. (42)
159 Adult (15–71 years) 
severe (GCS < 9) TBI
ELISA, 
unknown 
origin
Initially, 
3 days
Decreases over time, 
very slow decrease 
in control group 
not exposed to 
erythropoietin
None stated, 
>14 days in the 
control, 10–14 days in 
the treated group
Lower NSE levels over time in 
the erythropoietin group
McKeating  
et al. (80)
21 Adult (17–69 years) 
moderate-to-severe 
(GCS 3–13) TBI
LIA-mat 
system, 
Sangtec
24 h Decrease over time, up 
to 96 h
None stated, 
presumably >96 h
More volatility in patients with 
unfavorable outcome
Nirula  
et al. (82)
16 Adult mild-to-severe 
TBI
ILA system, 
Sangtec
24 h Decrease first 3 days, 
then stabilizing
None stated, 
presumably about 
48 h
Higher levels in patients with 
erythropoietin treatment
Olivecrona  
et al. (45)
48 Adult (15–63 years), 
severe (GCS 3–8) TBI
CLIA, Liaison, 
Sangtec
12 h Decrease the first 
3 days, then stabilizing
None stated, 
presumably about 
72 h
Worse correlation between NSE 
and S100B as time after trauma 
increases
Olivecrona and 
Koskinen (46)
48 Adult, severe 
(GCS < 9) TBI 
patients
CLIA, Liaison, 
Sangtec
12 h Decrease the first 
3 days, then stabilizing
None stated, 
presumably about 
72 h
APO-E4 patients lower NSE 
levels over time
Olivecrona  
et al. (47)
48 Adult, severe 
(GCS < 9) TBI 
patients
CLIA, Liaison, 
Sangtec
12 h Decrease the first 
3 days, then stabilizing
30 h is stated in 
discussion (no 
reference), but looks 
more like 72 h
Later NSE levels better for 
outcome prediction
(Continued)
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Reference Number 
of 
patients
Patient 
characteristics
NSe assay Sampling 
frequency
Trend over time Suggested reactive 
half-life
Notes
Pleines  
et al. (49)
13 Adult (16–67 years), 
severe TBI (GCS < 9)
ELISA, 
Sangtec
24 h Largely unchanged 
the first 14 days, slight 
decrease first day only
None stated, not 
possible to suggest 
based on the data
NSE not above reference levels
Raheja  
et al. (52)
86 Adult (18–65 years), 
severe TBI (GCS 4–8)
ELISA, DRG 
International
7 days Decrease the first 7 days None stated, <7 days NSE failed to show any 
significance to injury over time
Rodriguez-
Rodriguez  
et al. (54)
99 Adult, severe TBI 
(GCS 3–8)
ECLIA, 
Elecsys, 
Roche
24 h Decreasing the first 96 h, 
faster decrease with 
better outcome
None stated, 
presumably survivors 
about 24 h and non-
survivors about 72 h
48 h NSE is best for outcome 
prediction
Ross  
et al. (100)
51 (9 with 
serial 
sampling)
Adult, severe TBI RIA, custom 
made
Varying 
frequency 
(<24 h)
Generally constantly 
decreasing, one 
increasing
None stated, 
probably around 
24–48 h, shorter for 
some
Large spread, some patients 
have normal NSE levels without 
any good reason
Shahrokhi  
et al. (97)
32 Adult (18–60 years), 
male moderate-to-
severe TBI (GCS 
3–12)
ELISA, 
unknown 
origin
24 h to 
6 days
Few samples, decreases 
over time
None stated, <6 days No specific analysis on 
biomarker kinetics
Skogseid  
et al. (98)
60 (42 
mild TBI)
Adult, mild-to-severe 
TBI
RIA, custom 
made
Varying 
frequency, 
hours 
(<7 h)
Decreasing the first 12 h 
in a majority of patients, 
some steadily low, some 
increasing
None stated, difficult 
to assess
Extracranial injury lead to 
increased levels of NSE
Thelin  
et al. (11)
417 Adult (>14 years 
old), mild-to-severe 
(GCS 3–15) NICU TBI 
patients
CLIA, Liaison, 
DiaSorin
12 h Decreasing over the first 
60 h, faster in patients 
with favorable outcome
None stated, about 
24–48 h, longer in 
patients that died
NSE influenced by multitrauma 
over time. No specific time 
frame perfect for outcome 
prediction. More volatility and 
higher levels in patients with 
poor outcome
Vajtr  
et al. (94)
18 Unknown TBI ECLIA, 
Elecsys, 
Roche
>3 days Decreasing over the first 
7–10 days
None stated, 
probably 7–10 days
Decreasing quicker in patients 
who did not need neurosurgery
Woertgen  
et al. (66)
30 Adult (17–73 years), 
severe (GCS 3–8) TBI
ELISA, Wallac 
(maybe with 
RIA from 
Sangtec)
Initially 6 h Decreasing steadily to 
24 h, then fluctuating
None stated, 24–48 h Increasing levels of NSE in 
patients with high intracranial 
pressure
Yan  
et al. (61)
42 Adult (16–63 years), 
severe (GCS < 9) TBI
ELISA, CanAg 
Diagnostics
24 h Steadily decreasing the 
first 5 days to control 
levels
None stated, <24 h No specific analysis on 
biomarker kinetics
Zhao  
et al. (101)
128 Adult (16–72 years), 
severe (GCS < 9)  
TBI patients with 
diffuse axonal  
injury
Unknown >3 days Decreasing in the group 
(magnesium sulfate 
therapy), while it did not 
in the placebo group up 
to 7 days
None 
stated, > 7 days and 
even longer in the 
placebo group
Higher NSE levels in the 
placebo group
Zurek and 
Fedora (93)
63 Pediatric 
(0–18 years), 
presumably different 
severity of injury
ECLIA, 
Elecsys, 
Roche
24 h Steadily declining the first 
5 days, some outliers 
with higher levels
None stated, <48 h 
for a majority of 
patients. Some have 
secondary peaks
Higher levels in patients with 
more unfavorable outcome
Number of patients highlighted the total number of patients included in the study, sometimes highlighting in parenthesis how many were actually included with TBI or serial 
sampling. Patient characteristics described the age groups and injury severity level according to the GCS. The assay described the technique used for the assay and if available 
the manufacturer. Sampling frequency illustrates with what frequency samples were acquired. Trend over time highlights the specific temporal trajectory and dynamics for NSE. 
Suggested effective serum half-life is noted, as derived from graphs or tables. “Notes” indicate any specific considerations or notable findings of serial sampling in the specific article.
TBI, traumatic brain injury; ECLIA, electrochemiluminescent immunoassay; ELISA, enzyme-linked immunosorbent; GCS, Glasgow Coma Scale; ED, emergency department; ILA, 
Immunoluminometric assay; RIA, radioimmunoassay; CLIA, chemiluminescent immunoassays; ECLIA, electrochemiluminescent immunoassays; NSE, neuron-specific enolase.
TABLe 2 | Continued
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Assays Used to Analyze Serum NSE
Similar to S100B, the studies used to analyze NSE utilize a wide 
variety of different assays. A majority of studies used clinically 
available assays such as the LIA-mat system from Sangtec/
DiaSorin (11, 45–47, 74–76, 80, 82) or Elecsys/Cobas systems 
from Roche (54, 93, 94, 96), but commercial/custom made 
ELISAs (34, 42, 49, 52, 61, 66, 67, 77, 97, 102) and other tech-
niques (69, 71, 98–101) were also used. Comparable to results 
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of the S100B, the ELISA methods generally showed higher levels 
over time and with less dynamics, as compared to the automated 
assays (42, 49, 52, 97).
Sampling Frequency of NSE
Generally, NSE was sampled either every 6 h (66, 71, 98), 12 h (11, 
34, 45–47, 67, 102), and 24 h (54, 61, 74–77, 80, 82, 93, 96, 99, 100) 
in a majority of studies, while some reported longer sampling 
frequencies (42, 52, 69, 94, 97, 101).
Trend of NSE over Time after Trauma
Neuron-specific enolase has not been as extensively analyzed as 
S100B, but it shows similar characteristics with early high levels 
that decrease over time (34, 61, 69, 94, 97, 98, 100). However, 
the levels do not seem to decline with the same velocity as S100B 
(11, 42, 45–47, 49, 52, 69, 71, 74, 76, 80, 82) and even increase 
without any known association with outcome/injury in a few 
cases (77, 98, 99, 102). Nevertheless, a slower decline of NSE is 
seen in patient with more severe injuries or a more unfavorable 
outcome in many studies (11, 54, 66, 67, 93, 94, 96), and some 
increasing trajectories in patients with poor outcome were 
reported (66, 80, 93). Patients with concomitant extracranial 
injuries had higher levels of NSE (11, 98). Similar to S100B, 
secondary peaks of NSE were shown in some studies for patients 
with progressing injuries (75, 93). Likewise, some clinical trials 
noted a faster decrease of NSE in serum over time in the trial 
group as compared to placebo (34, 42, 101).
Suggested Serum t1/2 of NSE
Available data suggest that the serum t1/2 for NSE is longer than 
for S100B, presumably around 48–72 h in patients with severe 
TBI (11, 45–47, 54, 66, 71, 74, 76, 82, 93, 96) or even longer (42, 
75, 77, 80, 94) (Figure  2B). However, some studies reported a 
shorter t1/2 at 12 (34) or 24 h (61, 69, 100).
glial Fibrillary Acidic Protein
A search for GFAP identified a total of 1,953 manuscripts. 
Following removal of duplicates and after assessing full 
manuscripts, 18 articles were deemed eligible for final inclu-
sion (Figure S2 in Supplementary Material) and are listed in 
Table 3.
Patient Characteristics
Similar to studies analyzing S100B and NSE, the patient charac-
teristics of the GFAP patients were mixed, but with a preponder-
ance toward more severely injured patients (12, 52, 71, 77, 84, 
95, 103–110), even if milder cohorts also have been analyzed 
(92, 111, 112). Some studies looked partly, or solely, at pediatric 
cohorts (12, 113, 114).
Assays Used to Analyze Serum GFAP
A majority of the GFAP studies used various ELISA assays 
(12, 52, 77, 92, 104–107, 112–114), except two which used an 
ILA from Liaison™ (84, 108), two studies which used the Randox 
Biochip™ (109, 110), one an assay from Biotrak™ (95), one 
used a digital array from Quanterix™ (103), and two that used 
an immunoassay from MSD™ (71, 111). Currently, there are no 
clinically available assays. However, fully automated assays are 
under development.
Sampling Frequency of GFAP
Generally, GFAP was sampled every 24  h (77, 84, 104–110, 
113, 114) in a majority of studies (one outlier with 30 days between 
samples (103)), while some had as short as 6 h sampling (12, 71, 
92, 111), and one even 4 h initially (112). Two studies had longer 
sampling frequencies (52, 95).
Trend of GFAP over Time after Trauma
Similar to the previously studied markers, GFAP seems to 
decrease after trauma over time (71, 77, 95, 104, 105, 109, 110, 
113). However, some studies noted initially increasing levels, up to 
about 16–24 h following injury (84, 107, 108, 112). GFAP usually 
remained elevated for a prolonged period of time, as compared 
with S100B (12, 84). One study showed limited contribution of 
extracranial trauma (108). As with the other biomarkers, some 
studies noted prolonged elevated levels, or even continually 
increasing levels/volatile dynamics, in patients with unfavorable 
outcome or worse injuries (52, 71, 84, 104, 106–114).
Suggested Serum t1/2 for GFAP
The t1/2 for GFAP appears longer than for S100B, most studies 
reported a t1/2 at around 24–48 h in severe TBI patients (12, 77, 
84, 92, 104, 105, 107–110, 112–114), while some published data 
suggesting a shorter t1/2 (71, 106) (Figure 2C).
Ubiquitin Carboxy-Terminal Hydrolase L1
A search for UCH-L1 identified a total of 234 manuscripts. 
Following removal of duplicates and after assessing full manu-
scripts, nine articles were deemed eligible for final inclusion 
(Figure S3 in Supplementary Material) and are listed in Table 4.
Patient Characteristics
Generally, the patient characteristics in the UCH-L1 studies were 
somewhat trichotomized with some of the articles focusing more 
on the milder TBI spectrum (111, 112), while the others included 
primarily severe (12, 115–117), or a mix of TBI patients (92, 109, 
110) (Table 4). No pediatric TBI population was found.
Assays Used to Analyze Serum UCH-L1
Currently, no clinically available assays exist to analyze UCH-
L1 and all studies used different ELISAs, either custom made 
(12, 115–117) or commercially available (92, 112) except for two 
studies which used a Randox Biochip™ method (109, 110) and 
one with a ECLIA method from Banyan Biomarkers™ (111).
Sampling Frequency of UCH-L1
In comparison to the other proteins, most UCH-L1 studies had 
a 4–6 h (12, 92, 111, 112, 115, 116), or 12 h (117), sampling fre-
quency, allowing for a good estimate of the temporal profile. Two 
studies had a longer and varying sampling frequency (109, 110).
Trend of UCH-L1 over Time after Trauma
In unison with the other markers, UCH-L1 usually decreased 
steadily following TBI (12, 109, 110, 112, 116, 117). Secondary 
TABLe 3 | Analysis of GFAP studies.
Reference Number 
of 
patients
Patient 
characteristics
gFAP assay Sampling 
frequency
Trend over time Suggested 
effective 
half-life
Notes
Bogoslovsky 
et al. (103)
34 Adult, 21 mild + 13 
moderate-to-
severe TBI
Digital array, 
Quanterix
30–60 days Measured long after 
trauma, normalized in 
30 days
None stated, 
<30 days (in all 
patients)
Long-term biokinetics studied. Same 
GFAP levels as in healthy controls 
after 30 days
Di Battista 
et al. (71)
85 Adult moderate-to-
severe TBI
Multiplex 
immunoassay 
system, MSD
Initially, 
every 6 h.
Quickly declining GFAP, 
levels. Staying low after 
6 h
None stated, 
<6 h
First 24 h kinetics studied. Higher 
GFAP in patients with unfavorable 
outcome
Fraser  
et al. (113)
27 Pediatric severe 
TBI (GCS < 9)
ELISA, 
R-Biopharm
24 h Steadily declining. 
Normalizing on day 10
None stated, 
24 h the first 
days after injury.
First 10 days biokinetics, no 
monitoring. Higher GFAP in patients 
with unfavorable outcome
Honda  
et al. (77)
34 (18 TBI 
patients)
Adult ED TBI 
patients (GCS 
5–14)
ELISA, 
BioVendor
24 h Steadily declining first 
3 days
None stated, 
48–72 h
No GFAP level difference between 
diffuse and focal injury
Kou  
et al. (111)
9 Adult, mild TBI 
patients
ECLIA, MSD 6 h (up to 
24 h)
Decline and increase in 
two patients
N/A Worse dynamics in patient with 
worse white matter injury
Lei  
et al. (104)
67 Severe TBI patients 
(GCS 3–8)
ELISA, 
BioVendor
24 h Steadily declining first 
3 days, then normalizing
None stated, 
about 48 h
More volatile dynamics in patients 
with unfavorable outcome
Lumpkins  
et al. (105)
51 (39 with 
TBI)
Adult TBI patients ELISA, 
BioVendor
24 h Decreasing, but only 
samples on day 1 and 
day 2
<48 h GFAP levels second day better for 
outcome prediction. No monitoring 
aspect
Missler  
et al. (106)
25 Adult severe TBI 
(GCS < 7)
ELISA, custom 
made
24 h Increasing the first 24 h None, only 
increasing, all 
patients died 
within 24 h
Plasma and serum levels similar. 
Suggesting a very short half-life, 
shorter than for S100B
Mondello  
et al. (12)
81 Adult (including five 
pediatric) severe 
TBI patients, GCS 
3–8
ELISA, 
BioVendor
6 h Remaining elevated first 
24 h after injury
None stated, 
>24 h
Higher GFAP, with more volatile 
dynamic, in mass lesions vs diffuse 
injury
Nylén  
et al. (107)
59 Adult, severe TBI 
patients
ELISA, custom 
made
24 h Peak after 24 h, decline 
until 144 h (below 
reference)
None stated, 
probably around 
24 h
Outcome prediction better for later 
samples
Papa  
et al. (112)
325 
(35 TBI 
patients 
with 
injuries)
Adult mild-to-
moderate TBI (GCS 
9–15)
ELISA, Banyan 
Biomarkers
Initially, 
every 4 h
Peak after 16 h, decline 
until 132 h
None stated, 
probably around 
32 h
More volatile dynamics in patients 
with injuries and requiring intervention
Pelinka  
et al. (84)
92 Adult mild-to-
severe TBI patients
ILA, LIAISON, 
Sangtec
24 h Decreasing steadily in 
non-survivors, peaking 
12–36 h after trauma in 
survivors
None stated, 
61–84 h in non-
survivors and 
around 24–48 h 
in survivors
Later samples better outcome 
predictor
Pelinka  
et al. (108)
114 Adult mild-to-
severe TBI patients
ILA, LIAISON, 
DiaSorin
24 h Similar to Pelinka et al. 
(84)
Similar to Pelinka 
et al. (84)
Similar to Pelinka et al. (84)
Posti  
et al. (109)
324 (71 
patients 
with injury)
Adult mild-to-
severe TBI patients
Randox 
Biochip, 
Randox 
Laboratories
Initially, 
every 24 h
Moderate-to-severe TBI 
decreasing while mild TBI 
steady
None stated, 
moderate-to-
severe TBI about 
24 h
Early samples best for outcome 
prediction
Raheja  
et al. (52)
86 Adult (18–
65 years), severe 
TBI (GCS 4–8)
ELISA, 
BioVendor
7 days Patients with favorable 
outcome decreasing, 
unfavorable constant the 
first 7 days
None stated, 
<7 days probably
Day 7 samples of GFAP had good 
precision for outcome prediction
Takala  
et al. (110)
See Posti 
et al. (109)
See Posti et al. 
(109)
See Posti et al. 
(109)
Initially, 
every 24 h
See Posti et al. (109) See Posti et al. 
(109)
See Posti et al. (109)
Vajtr  
et al. (95)
38 Adult, severe TBI 
patients
Biotrak Activity 
Assay System
>3 days Decrease from 1–3 to 
4–10 days
None stated, 
<10 days
No specific findings related to 
dynamics, expansive contusions 
highest levels of GFAP
(Continued)
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TABLe 4 | Analysis of UCH-L1 studies.
Reference Number 
of 
patients
Patient 
characteristics
UCH-L1 
Assay
Sampling 
frequency
Trend over time Suggested 
effective half-life
Notes
Blyth  
et al. (117)
16 Adult ED TBI 
patients (GCS 
3–15)
ELISA, custom 
made
Every 12 h Constantly decreasing 
on group level
None stated, 
probably about 10 h
Blood–brain barrier assessment 
with biomarker measurements 
over time
Brophy  
et al. (115)
86 Adult severe TBI 
(GCS 3–8)
ELISA, custom 
made
Every 6 h Constantly decreasing 
on group level
7–9 h Longer half-life in patients with 
more severe injury and worse 
outcome
Kou  
et al. (111)
9 Adult mild TBI 
patients
ECLIA,  
Banyan 
Biomarkers
Every 6 h (up 
to 24 h later)
Slight increase in a 
patient with brain 
hemorrhage
N/A GFAP and UCH-L1 are correlated 
with extent of white matter injury
Mondello  
et al. (12)
81 Adult severe TBI 
patients (GCS 3–8)
ELISA, custom 
made
Every 6 h Constantly decreasing None stated, 
probably about 
10–12 h
Focal injuries faster decrease of 
UCH-L1
Mondello  
et al. (116)
95 Adult severe TBI 
patients (GCS 3–8)
ELISA, custom 
made
Every 6 h Constantly decreasing 
on group level, early falls 
first 12 h
None stated, 
probably about 10 h
Earlier UCH-L1 levels better for 
outcome prediction
Papa  
et al. (112)
325 
(35 TBI 
patients 
with 
injuries)
Adult mild-to-
moderate TBI (GCS 
9–15)
ELISA, Banyan 
Biomarkers
Initially, every 
4 h
Constantly decreasing 
on group level
None stated, 
probably 5–7 h first 
24 h. Normalized in 
about 48 h
Slower decrease of UCH-L1 
concentrations in patients 
with hemorrhage and need for 
intervention
Posti  
et al. (109)
324 (71 
patients 
with injury)
Adult mild-to-
moderate TBI (GCS 
3–15)
Randox 
Biochip, 
Randox 
Laboratories
Initially, every 
24 h
In severe-to-moderate 
TBI, decreasing first 
3 days, constant in 
mild TBI
None, difficult to 
assess from study, 
<24 h
Earlier samples better accuracy for 
injury severity than later samples
Takala  
et al. (110)
See Posti 
et al. (109)
See Posti et al. 
(109)
See Posti et al. 
(109)
Initially, every 
24 h
See Posti et al. (109) See Posti et al. (109) See Posti et al. (109)
Welch  
et al. (92)
167 (33 
patients 
with 
injuries)
Adult mild-to-
moderate TBI (GCS 
9–15)
ELISA, Banyan 
Biomarkers
Every 6 h (up 
to 24 h later)
Serum concentrations in 
patients with brain injury 
constant first 12 h, then 
decreasing
None, many outliers 
with constant or 
increasing levels.  
A peak is seen at 8 h
No specific kinetic analysis other 
than faster decreasing in non-TBI 
patients
Number of patients highlighted the total number of patients included in the study, sometimes highlighting in parenthesis how many were actually included with TBI or serial 
sampling. Patient characteristics described the age groups and injury severity level according to the GCS. The assay described the technique used for the assay and if available 
the manufacturer. Sampling frequency illustrates with what frequency samples were acquired. Trend over time highlights the specific temporal trajectory and dynamics for UCH-L1 
Suggested effective serum half-life is noted, as derived from graphs or tables. “Notes” indicate any specific considerations or notable findings of serial sampling in the specific article.
TBI, traumatic brain injury; ECLIA, electrochemiluminescent immunoassay; ELISA, enzyme-linked immunosorbent assay; GCS, Glasgow Coma Scale; ED, emergency department; 
GFAP, glial fibrillary acidic protein; UCH-L1, ubiquitin carboxy-terminal hydrolase L1.
Reference Number 
of 
patients
Patient 
characteristics
gFAP assay Sampling 
frequency
Trend over time Suggested 
effective 
half-life
Notes
Welch  
et al. (92)
167  
(33 patients 
with 
injuries)
Adult mild-to-
moderate TBI (GCS 
9–15)
ELISA, Banyan 
Biomarkers
Every 6 h 
(up to 24 h 
later)
Only increasing the first 
24 h
None stated, 
probably >24 h
Serum concentrations of GFAP less 
influenced by temporal changes than 
other biomarkers
Zurek and 
Fedora (114)
59 Pediatric 
(0–19 years) severe 
TBI (GCS < 9).
ELISA, 
BioVendor
24 h Generally decreasing 
the first 3 days, some 
outliers with dynamic 
concentrations over time
None stated, 
probably 24–48 h
Higher levels over time resulted in a 
general worse outcome
Number of patients highlighted the total number of patients included in the study, sometimes highlighting in parenthesis how many were actually included with TBI or serial 
sampling. Patient characteristics described the age groups and injury severity level according to the GCS. The assay described the technique used for the assay and if available 
the manufacturer. Sampling frequency illustrates with what frequency samples were acquired. Trend over time highlights the specific temporal trajectory and dynamics for GFAP. 
Suggested effective serum half-life is noted, as derived from graphs or tables. “Notes” indicate any specific considerations or notable findings of serial sampling in the specific article.
TBI, traumatic brain injury; ECLIA, electrochemiluminescent immunoassay; ELISA, enzyme-linked immunosorbent assay; GCS, Glasgow Coma Scale; ED, emergency department; 
ILA, immunoluminometric assay; GFAP, glial fibrillary acidic protein.
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TABLe 5 | Analysis of NF-L studies.
Reference Number 
of 
patients
Patient 
characteristics
NF-L assay Sampling frequency Trend over time Suggested 
effective 
half-life
Notes
Al Nimer et al. (13) 182 Adult NICU TBI 
patients
ELISA, Uman 
Diagnostics
Varying frequency first 
2 weeks
Constantly increasing, 
unchanged over first week
N/A No special 
monitoring aims
Shahim et al. (56) 72 Adult TBI patients, 
GCS 3–8
Simoa, 
Quanterix
Initially, every 24 h Constantly increasing, group 
level
N/A No special 
monitoring aims
Number of patients highlighted the total number of patients included in the study, sometimes highlighting in parenthesis how many were actually included with TBI or serial 
sampling. Patient characteristics described the age groups and injury severity level according to the GCS. The assay described the technique used for the assay and if available 
the manufacturer. Sampling frequency illustrates with what frequency samples were acquired. Trend over time highlights the specific temporal trajectory and dynamics for NF-L. 
Suggested effective serum half-life is noted, as derived from graphs or tables. “Notes” indicate any specific considerations or notable findings of serial sampling in the specific article.
TBI, traumatic brain injury; NICU, neurointensive care unit; ELISA, enzyme-linked immunosorbent assay; Simoa, single molecule array; N/A, not available; NF-L, neurofilament light; 
GCS, Glasgow Coma Scale.
15
Thelin et al. Serial Sampling of TBI Biomarkers
Frontiers in Neurology | www.frontiersin.org July 2017 | Volume 8 | Article 300
peaks, or increasing trajectories in patients with serious injuries, 
were found in patients in a few papers (92, 111, 112, 115, 116). 
One study suggested that UCH-L1 peaks at around 8  h after 
injury (92).
Suggested Serum t1/2 of UCH-L1
Looking at the available data, the serum t1/2 seems to be about 
10  h (12, 112, 116, 117) in severe TBI patients, a few hours 
shorter in milder cases (112) (Figure 2D). In comparison to 
the other markers, UCH-L1 actually had one study with the 
goal of establishing a “half-life” of UCH-L1, which was given 
at 7–9 h (115) in severe TBI patients. This was found shorter 
in milder TBI cohorts, where data indicated that it was around 
6 h (115).
Neurofilament Light
A search for NF-L identified a total of 575 manuscripts. Following 
removal of duplicates and after assessing full manuscripts, only 
n = 2 articles were deemed eligible for final inclusion (Figure S4 
in Supplementary Material) and are listed in Table 5.
Patient Characteristics
Only two studies were included which both presented NICU 
TBI materials with mixed TBI severity according to GCS admis-
sion (Table 5) (13, 56). No pediatric TBI population has been 
studied.
Assays to Analyze NF-L
Officially, there are currently no available ELISAs for NF-L in 
serum. One of the included studies instead used an ELISA assay 
developed for CSF samples (13), and the other used the newly 
developed single molecule array technique to create a functional 
assay (56).
Trend of NF-L over Time after Trauma
In contrast to the other serum biomarkers, the two available 
studies suggest that NF-L levels in serum in a mild-to-severe 
(and one severe) TBI cohort of NICU patients tend to increase 
over time during the first 1–2 weeks (increased during the whole 
sampled period) (13, 56). Additionally, some patients were found 
to have elevated levels even 1 year after trauma (56).
Suggested Serum t1/2 of NF-L
With the data available, it is not possible to determine a serum t1/2 
for NF-L (13, 56). However, it is evident that this is the protein 
with the longest t1/2 of these biomarkers.
DiSCUSSiON
This systematic review highlights that serial sampling of dif-
ferent biomarkers in serum results in distinguishably different 
temporal trajectories in TBI patients. Serum S100B and UCH-
L1 levels seem to have the shortest t1/2 while the serum levels 
of the biomarkers GFAP and NSE both remain elevated for a 
prolonged period of time, as compared to S100B and UCH-L1. 
Even more extended, NF-L appears to have the longest t1/2 of 
the biomarkers. However, a specific value could not be identi-
fied in the studies, as it continued to increase over the sampling 
period of 2 weeks. Due to the heterogeneity of included patients, 
secondary brain injury development, assays used, and sampling 
frequency, it is impossible to draw any accurate conclusions 
regarding standardized elimination half-lives after concentra-
tion peaks for these proteins, but we believe our effort including 
effective half-lives provides the best possible attempt to date. 
Moreover, different sources of biomarkers seem to influence 
the total serum levels over time, with extracranial contribution 
being most influential for S100B and NSE, where this has been 
most extensively studied. Despite these caveats and in contrast 
to the other biomarkers, S100B and NSE have fully automated 
clinical assays, making them accessible for routine clinical use. 
To our knowledge, this is the first systematic review of temporal 
profiles of biomarkers following TBI, and it could serve as a 
platform to better assess and compare novel brain biomarkers 
to be introduced, as well as relate future studies presenting serial 
sampling of TBI patients.
Unsurprisingly, the searches that generated the greatest 
numbers of research articles were that of S100B and NSE. These 
markers are by far the most studied in TBI but have also been 
studied in other intracranial conditions, mainly in stroke (118) and 
to assess brain injuries in patients suffering from circulatory arrest 
(119). Regarding different aspects of the temporal trajectories, 
S100B is by far the most studied. It is becoming increasingly clear 
that temporal changes of S100B in serum are highly dynamic 
FigURe 3 | Protein kinetics following injury. Highlighting the estimated 
temporal profile from trauma if frequently sampled. Initially, there will be a 
major release of the protein from extracranial sources (gray line), in theory 
more so if it is present to a larger extent in tissue likely to be injured (i.e., 
S100B in adipose tissue), even if this contribution generally decreases rapidly. 
The cerebral contribution (blue line) will continue to increase in serum (for 
S100B up to 27 h), presumably due to influx from the injured brain. In case  
of ongoing injury development, the subsequent serum samples may have a 
prolonged decline or even continue to increase depending on the injury 
severity (red line). In case of a new injury development, secondary peaks 
have been shown (green line). While this pattern is most studied for S100B,  
it applies to some extent to all the biomarkers even if the time frames are 
different.
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following brain injury (39, 66, 73, 120). Figure 3 is an attempt 
to better illustrate these changes, and while it is constructed with 
the dynamics of S100B in mind, it may be generally applicable to 
the other biomarkers as well, but with different t1/2. The exception 
is NF-L, where the t1/2 is so long that it has not yet even been 
estimated. The highest levels of S100B are seen early (within 
60–120 min after trauma) in patients suffering from multitrauma 
where bone, adipose tissue, and internal organs [tissues known to 
express S100B as well (121, 122)] are injured (11, 48). However, 
these extracranial contributions of S100B will decrease rapidly, 
as is seen in patients with only multitrauma and without brain 
injury (48). Jackson et al. estimated these rapid falls of S100B to 
have a serum “half-life” of 198 min (first sample within 60 min) 
(39). Townend et al. looked at S100B in mild TBI patients and 
found that S100B only had an estimated “half-life” of 97 min, even 
though these samples were acquired a bit later after trauma (CI: 
75–136 min, first sample within 240 min following trauma) and 
all did not have structural injuries (37). In our own experience, 
the highest level of S100B in serum we have seen was 23.0 µg/L 
(healthy reference < 0.11 and 1.0–2.0 µg/L usually seen in severe 
TBI patients) sampled 29 min following trauma from a patient 
who had fallen from the fifth floor and had severe extracranial 
injuries as well as intracranial focal mass lesions [patient in 
study (11)]. The next sample was 6.2 µg/L acquired 6.5 h after 
trauma, suggesting a “half-life” similar to Jackson et al. of around 
3 h. It is import to realize that levels of S100B may represent two 
processes, where the initial early peak probably represents a more 
bolus-like dose of S100B assumed predominantly of extracranial 
origin and is eliminated quickly (Figure 3), here better reflect-
ing its true serum elimination half-life. The second peak, after 
about 24 h, represents a slow release net sum of influx and outflux 
of S100B to serum, predominantly from the injured brain and 
where the slower decay is affected by the continued release, thus 
the extended t1/2. This interpretation is supported by our study 
of moderate-to-severe TBI patients, where we saw that the late 
24 (27.2)-h peak is highly related to outcome whereas the initial 
peak is not (11). We have also modeled the functional kinetics of 
S100B in moderate-to-severe TBI patients, after excluding this 
initial “trauma peak” (73). S100B was found to have an expected 
“brain injury” peak level at around 27 h after injury (38). After 
that peak, it should drop with an expected rate during the upcom-
ing days (38). If S100B does not follow this trajectory, it could 
indicate ongoing brain injury (9, 43, 44), resulting in an unfavora-
ble outcome (11). We must stress that the trajectory described 
here is that of TBI and has not been extensively studied in other 
contexts. Our experience of several thousand patients in routine 
clinical use, in for example patients with embolic stroke, is that 
they can express an extended release, often peaking at day 2–3. 
The cause of this is not yet understood, but could reflect ongoing 
penumbral leakage or patterns of recirculation. The presence of 
secondary peaks of S100B should be highlighted (7, 8, 44–46), 
as they have been shown to be associated with secondary brain 
injuries or neurological deterioration in TBI patients. In sum-
mary, it is important to understand the kinetic profile of S100B, 
and its different components when interpreting it as a biomarker 
of brain injury.
The second most studied protein was NSE. Similar to S100B, a 
steady decline is generally seen but with a serum t1/2 longer than 
for S100B. However, patients with severe injuries may continue 
to present increasing levels in serum after trauma (47, 48). The 
general decrease seen for NSE may be delayed in patients with 
unfavorable outcome or more severe injuries (11, 44), and NSE 
has been shown to be influenced by extracranial contribution 
(11, 49), possibly more so than S100B. Another major caveat 
with NSE is its presence in erythrocytes making serum sampling 
unreliable if hemolysis is present (50) despite that there are tools 
attempting to adjust for this (51) and procedures in automatic 
clinical assays that discard. Similar to S100B, secondary peaks 
of NSE have been shown in patients with new or progressing 
injuries (44, 52). In aggregate, NSE behaves similar to that of 
S100B in serum, albeit it appears to have a longer contextual 
half-life in serum of about 48 h and has larger influence from 
extracranial sources.
Serial sampling of GFAP has been less commonly studied 
in TBI, but interest is increasing, presumably due to GFAP’s 
superior brain specificity (41). The serum t1/2 levels of GFAP are 
extended, as compared to S100B, presumably at around 24–48 h 
in severe TBI patients and thus similar to NSE. This prolonged 
increase in serum levels may prove to be beneficial for diagnos-
tic screening of intracranial lesions in milder TBI, being more 
detectable >6  h after injury, as compared to S100B (53, 54). 
However, it appears to lack granularity to detect more rapidly 
changing trajectories as seen when serially sampling proteins 
with shorter effective half-lives, such as S100B and UCH-L1. 
This may explain why only a limited amount of studies report 
secondary peaks of GFAP (12). A long t1/2 will make it difficult 
to use in assessment of treatment efficacy and monitoring, as 
it would in theory provide a delayed treatment response and 
show a blunted concentration. Despite this, a delayed decrease 
TABLe 6 | Characteristics of the selected protein biomarkers.
Protein Molecular 
weight
Primary 
origin
Automated 
assay
extracranial 
contribution
effective 
serum half-life
Clinical relevance
S100B 9–11 kDa Astrocytes Available Relatively high Short (hours up 
to 24 h)
+ Effective for serial sampling and monitoring purposes, can detect 
secondary deterioration.
+ Well validated in the literature.
− Extracranial contribution lowers its potential early after 
multitrauma.
Neuron-specific 
enolase
47 kDa Neurons Available Relatively high Long 
(24 h–3 days)
+ Rather well validated in the literature, have been shown to detect 
secondary deterioration.
− Hemolysis leads to high levels in serum.
− Extracranial contribution lowers its potential in multitrauma.
− Relatively long effective half-life limits the potential for monitoring.
Glial fibrillary 
acidic protein
50 kDa Astrocytes Not available Very low Long 
(24 h–2 days)
+ Low extracranial contribution.
+ Rather well validated in the literature, have been shown to detect 
secondary deterioration.
− Relatively long effective half-life limits the potential for monitoring.
Ubiquitin 
carboxy-terminal 
hydrolase L1
25 kDa Neurons Not available Low Short (hours up 
to 12–24 h)
+ Low extracranial contribution.
+ Should be effective for serial sampling and monitoring purposes 
because of short effective half-life.
− Limited validation in the literature, but has been shown to detect 
secondary deterioration.
Neurofilament 
light
68–70 kDa Neurons Not available Very low Very long 
(3 weeks?)
+ Low extracranial contribution.
− Very long effective half-life limits the potential for monitoring.
− Limited validation in the literature.
Illustration of some of the protein characteristics. Primary origin indicates which cell in the central nervous system contain highest amount of the specific protein. Molecular weight 
is the size of the protein in kilo Dalton and the primary cellular origin is the cells with highest amount of expressed concentration in the central nervous system. If an automated 
clinical assay platform is available, it is indicated. Extracranial contribution is an aggregate from Table S1 in Supplementary Material, indicating how much protein and mRNA that is 
expressed outside the central nervous system. Serum effective half-life is an aggregate of the findings in this study. Clinical relevance is exemplified.
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or continued release of GFAP is seen in patients with unfavora-
ble outcome (53, 55–57). Patients with mass lesions appear 
to have higher levels of GFAP in serum as compared to more 
diffuse injuries (12, 58), especially in combination with lower 
levels of UCH-L1 (used in a glial:neuronal ratio) (59). While 
GFAP has been seen to increase in patients with extracranial 
trauma and without brain injury (60), reports of serial sam-
pling in multitrauma populations are scarce (108), but as the 
protein is so much more brain specific as compared to S100B 
(Table S1 in Supplementary Material; Table  6) (41), available 
data suggest that extracranial contribution over time to be rela-
tively low. In summary, GFAP seems to have longer t1/2 half-life 
than S100B, of about 24–48 h, which might prove beneficial for 
screening purposes if a patient is sampled late after ictus, but 
might decrease accuracy to detect and separate novel lesions 
and monitor ongoing events.
Brophy et al. analyzed serum levels of UCH-L1 with a high 
sampling frequency and established its serum functional half-life 
to be in the vicinity of 7–9 h (115). They also noted it to differ 
between severe and mild injury. Moreover, similar to the other 
markers, they discovered some individual patients with secondary 
increases (29, 61). This decrease was slower in patients with more 
severe injuries and worse outcomes (29, 53), also analogous with 
the other biomarkers. Interestingly, and in contrast to GFAP, dif-
fuse injury seems to lead to higher levels of UCH-L1 as compared 
to focal mass lesions (12). UCH-L1 is more brain specific than 
S100B (41), but data indicate that it is also significantly increased 
in patients with extracranial injuries (60). In aggregate, UCH-L1 
appears to have a relatively short functional half-life, similar to 
that of S100B, but needs further studies to elucidate its temporal 
profile following trauma as well as more robust associations with 
extracranial injuries.
The protein NF-L is the least studied in a temporal context, 
presumably because no commercial assay is available at present. 
The two studies investigating this biomarker in TBI populations 
noted that serum levels of NF-L continually increased the first 
week(s) after injury (13, 34). There are no in vivo studies that 
have appropriately assessed the serum half-life of NF-L, but an 
in vitro report suggests that it may be as long as 3 weeks (62), 
which could be possible looking at available data. Surprisingly, 
it was found elevated even at up to a year in some patients (34), 
perhaps indicating ongoing pathology. Neurofilament heavy 
(NF-H) is another, similar, axonal protein that has been studied 
in TBI and shows similar trends with continually increasing 
serum levels the first days after trauma (63). A case series sug-
gests that NF-L may aid in assessment of diffuse axonal injury 
(64), and a study indicates that it adds independent information 
in outcome prediction models, in addition to S100B (13). As 
reliable assays become more readily available, there might be a 
growing interest in this marker, which could reflect an ongoing 
neuroinflammatory pathology, distinctly different to the oth-
ers studied here. However, considering its serum dynamics, it 
would probably provide little information on the rapid develop-
ment of novel intracranial lesions the first week in the NICU 
but would instead be of greater interest in later, more chronic 
phases of TBI.
FigURe 4 | Protein kinetics for each protein in serum over time. Graph 
illustrating how the influence of an increasing effective half-life results in a 
serum sample in an uneventful traumatic brain injury (TBI) (without secondary 
deterioration) for ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) (red), 
S100B (black), neuron-specific enolase (NSE)/glial fibrillary acidic protein 
(GFAP) (blue), and neurofilament light (NF-L) (green). Biomarker concentration 
in serum on y-axis and time in hours on x-axis. Note that these are estimates 
based on the knowledge of S100B kinetics in serum, current literature makes 
it difficult to illustrate more accurate trajectories over time for the other 
proteins.
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In Table 6, we present an aggregate of our findings on these 
markers. Our review finds the effective serum half-lives of 
these biomarkers to be similar in ranges to those suggested by 
a recently published narrative review of the field where, among 
others, S100B, NSE, GFAP, and UCH-L1 were included (65). In 
contrast to that narrative review, we have focused on the serum 
compartment, attempting to systematically interpret information 
on effective half-lives from all available studies. While it was 
impossible to conduct a proper meta-analysis, we summarized 
the available literature in histograms for S100B (Figure  2A), 
NSE (Figure 2B), GFAP (Figure 2C), and UCH-L1 (Figure 2D), 
where it is possible to see that S100B and UCH-L1 have the 
most amount of studies that indicate a shorter effective serum 
half-life while GFAP and NSE exhibit relatively longer serum t1/2 
(Figure 4). 
Many factors could affect the contextual half-lives of the 
studied biomarkers, and we acknowledge that the serum effec-
tive half-lives provided here might still be inaccurate. While we 
excluded studies without structural imaging, we did not look at 
lesion progression as only one study properly reported this (9), 
something we believe will influence trajectories of serially sam-
pled proteins. The association between lesion size and biomarker 
levels was also barely mentioned (66). Together, these conditions 
make it difficult to accurately generate a precise half-life due to 
the constant influx/efflux of the proteins to the serum compart-
ment (20). Furthermore, some studies suggest peak times of 
biomarkers as related to time after trauma (73, 102, 112, 115). 
Currently, S100B is the only protein where attempts have been 
made to model the temporal contextual kinetics following injury 
(73), something that also needs to be performed for the others. 
We believe that all of these serum proteins, except for NF-L, 
peak relatively early in serum and any unexpected prolonged 
release might not be a natural progression but could indicate 
deterioration or ongoing damage in some way. Moreover, it 
is unknown to what extent these proteins are expressed after 
trauma, also potentially affecting levels. Additionally, extracra-
nial injuries give rise to some of these proteins in serum as well, 
primarily NSE and S100B, resulting in altered serum dynamics 
(11, 48). While UCH-L1 and GFAP have been shown to be 
increased in serum of non-head injured patients as well (123), 
they are, together with NF-L, more brain specific (122). We show 
this in Table S1 in Supplementary Material, where we have gath-
ered protein and mRNA expression (in tissues usually injured 
in multitrauma patients). In aggregate, extracranial contribution 
and injury progression need to be better assessed in future stud-
ies as it will affect contextual kinetics.
Several articles mentioned refer to the term “serum half-life” 
when trying to describe the temporal profiles following TBI. We 
believe that this description is inaccurate as we are not looking at 
protein decay in a single space; instead it is probably a combination 
of influx and efflux between bodily compartments with ongoing 
release from the injured brain, where actual clearance is one of 
many actors (20). Thus, we have used the term “effective serum 
half-life” to describe that concentration dynamics is presumably 
more accurate as this is not a process with constant decay (i.e., as 
is true in theory for a biological half-life).
We could not find any signs that younger patients should 
have a different temporal profile than adults for these proteins. 
Instead, and as can be seen in the tables, biomarker dynamics 
in serum appear to be correlated with injury severity. However 
and notably, pediatric populations were not nearly as frequently 
studied as adult TBI patients. The reference levels for healthy 
pediatric populations (especially the first year) of S100B and 
NSE have both been shown to be significantly higher than for 
adults (factor ×2–4) (124, 125). Nevertheless, during traumatic 
conditions, similar trajectories to adults are seen in pediatric 
populations, and serum dynamics are likely a marker of injury 
severity and progression not requiring separate reference levels 
per age group. In aggregate, age does not seem to play a major 
role in biomarker serum dynamics, but is not as well studied in 
pediatric populations as compared to adults.
The literature varies greatly in terms of the sampling frequency 
chosen. This may be problematic when attempting to determine 
the detailed kinetics. For many studies, the generally long sam-
pling intervals chosen severely limit our knowledge of its early 
behavior. The choice of optimal sampling frequency to ensure 
faithful replication of a time series has received extensive inves-
tigation in information theory (126). In essence, the sampling 
frequency must be chosen to be at least twice the characteristic 
frequency of the signal. In other words, if changes are expected 
over a particular time period, then the sampling interval must 
be at most half of this and preferably more frequent still. Thus, 
we suggest that future prospective studies consider the following 
issues:
 – Sampling frequency: It is best advised to perform a high initial 
sampling frequency to accurately map trajectories over time 
(proteins like S100B/UCH-L1 needs a higher frequency than 
NF-L). If early detection is the goal, then a tapered strategy 
may help identify peak with early frequent sampling.
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 – Relations to imaging: A high frequency of imaging will best 
aid association of biomarker trajectories with potential injury 
progression. Current imaging modalities in practice limit the 
frequency possible.
 – Relations to other monitoring: High frequency multimodal 
monitoring (metabolism, oxygenation, intracranial pressure, 
etc.) may help associate biomarker trajectories with potential 
secondary insults/deterioration.
 – TBI population: We suggest to identifying and studying TBI 
cohorts that are clinically and pragmatically definable such as 
NICU TBI patients, thus aiming to understand a biomarker 
in the context of the population it is expected to be clinically 
used in.
 – Blinding: Serum biomarkers should be analyzed in retrospect 
or blinded as to not influence treatment strategies in a study 
setting.
 – Analysis method: If possible, use a well validated assay, prefer-
ably with industrial-level calibration.
Readily available and reliable assays are crucial if protein bio-
markers are to find routine clinical application. To date, automated 
assays with industrial calibrations are only available for S100B 
and NSE, and this makes it possible to provide reliable analyses 
in less than 20 min from sampling. Until this is widespread, it will 
be difficult for the other proteins to reach everyday use as these 
assays (i.e., ELISAs) take around 6 h or more to run. Moreover, 
without proper automatic assays with regular, standardized 
calibrations, there is a risk for greater inter- and intravariability 
between samples and studies, as has been seen between ELISA 
methods for S100B (67). Actually, we noticed that several studies 
that did use ELISA for NSE and S100B showed a different release 
pattern after trauma with consisting higher levels over time, as 
compared to the automated assays, resulting in longer serum 
half-lives (66, 68, 69). This is worrying as it may imply that the 
assays (and thus the studies) are not as comparable as has been 
suggested, presumably due to different antibodies used or differ-
ent lower levels of detection, stressing the need for standardized 
testing in the field. Likely, while we did not particularly focus on 
the exact levels but on the temporal profiles, they would also be 
affected by this.
Limitations
We aimed to perform a meta-analysis of the data collected but 
realized that this was not possible primarily due to the use of 
different assays, differences in sampling time and heterogene-
ous patient populations. Instead, we have listed estimates of 
serum half-lives by assessing graphs, tables, and data sets from 
previous studies, which we believe generates the best possible 
current estimates of the effective serum half-lives of these 
proteins after TBI.
Studies of S100B and NSE are more frequent than studies 
analyzing UCH-L1 and NF-L. Results concerning the proteins 
with little data should be interpreted with more caution. In the 
case of NF-L, only two studies were available and the uncer-
tainty is large here. Indicative of this is that in contrast to the 
findings on NF-L, NF-H has been found to have a short half-life 
in mild TBI t1/2 (48–72 h) (127). As these two components may 
have similar half-lives and as no mild TBI study is available for 
NF-L, it is possible that NF-L has a shorter t1/2 in this population 
as well.
It is possible that several papers coming from the same research 
centers contain, to some extent, the same patients several times. 
We have not been able to adjust for this possibility. We mention all 
studies in the tables but focus on the largest patient cohort from 
each group in the Section “Discussion.”
While we have acknowledged a difference in sampling fre-
quency between basically all studies, one further issue is that a 
majority of studies report sampling since admission, not from the 
actual trauma time. As the dynamics for a protein such as S100B 
differs substantially in time the first 24 h (38), having the exact 
trauma time reported is essential to generate adequate models of 
biomarker release.
CONCLUSiON
It is increasingly apparent that the dynamic behavior of serum 
TBI biomarkers varies greatly and an appreciation of this is 
critical for their interpretation as markers of tissue fate. The initial 
intracranial injury, potential extracranial trauma as well as injury 
progression and the occurrence of secondary injuries will influ-
ence the biomarker temporal profile. Unfortunately, while serial 
sampling is common in studies, few adequately comment on the 
temporal profiles of the analyzed proteins and even less address 
what sampling frequency is needed to capture information 
content. From a clinical perspective, and with the aim of using 
biomarkers as ongoing monitors of TBI patients, proteins with 
shorter serum availability such as S100B and UCH-L1 may be 
advisable as compared to proteins such as NSE, GFAP, and NF-L, 
as the longer peak times and half-times may lag detection of sec-
ondary harmful events. Moreover, brain specificity of the proteins 
should be taken into account and the need for fast, reliable assays 
is the definite current rate-limiting step in research that may lead 
biomarkers to clinical use. Further prospective research on the 
contextual kinetics of protein biomarkers is urgently warranted if 
their full diagnostic potential is to be realized.
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